From different studies we know that more than 92% of drug candidates for Central Nervous System diseases fail in clinical trials, with 34% of safety failure. All that candidates have successfully passed in vitro steps and animal testing. Conclusion is straightforward : we have to deeply change biological models in vitro assays, and taking in account the 3D nature of human organs and the importance of the matricial microenvironment.

In HCS Pharma, we have developed more effective human 3D cellular models, fully compatible with High Content Screening and with the aim to better select drug candidates. Our technology, BIOMIMESYS® Brain associates the behavior of a solid scaffold and of a hydrogel. It provides a cell culture microenvironment reproducing all aspects of human tissues, including matrix architecture, cellular organization, cell-cell and cell-matrix interactions.

You can find more information on :

You can also join us in the next free webinar to see results and ask your questions : “The importance of microenvironment of neurons highlighted with BIOMIMESYS® Brain”, October 4 & 6

If you have comments or specific questions, feel free to ask!

Grégory MAUBON

Grégory MAUBON is Chief Data Officer and digital coordinator at HCS Pharma, a biotech startup focused in high content screening and complex diseases. He manages IT missions and leads digital usages linked to company needs. He is also a Augmented Reality Evangelist (presenter and lecturer) since 2008, where he created and founded in 2010 RA'pro (the augmented reality promotion association). He helped many companies (in several domains) to define precisely their augmented reality needs and supported them in the implementation.


Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.